Amiodarone-an "old" drug with new recommendations

Michele R McKee1

  • 1Pediatric Emergency Medicine, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010, USA. mmckee@cnmc.org

Insights

Amiodarone is an antiarrhythmic drug recommended for pediatric resuscitation. Current pediatric data show limited efficacy, indicating a need for more research before widespread clinical acceptance.

Area of Science:

  • Cardiology
  • Pediatric Emergency Medicine
  • Pharmacology

Background:

  • Amiodarone is an antiarrhythmic medication gaining attention following revised pediatric resuscitation guidelines.
  • While adult use is well-supported, pediatric data on amiodarone efficacy is limited.
  • There is a critical need for more research on amiodarone in pediatric acute resuscitation.

Purpose of the Study:

  • To review amiodarone properties relevant to pediatric resuscitation.
  • To analyze existing pediatric studies on amiodarone's efficacy and safety.
  • To provide healthcare providers with information for informed antiarrhythmic choices in pediatric emergencies.

Main Methods:

  • Literature review of amiodarone properties.
  • Analysis of published pediatric studies concerning amiodarone use in resuscitation.
  • Discussion of the challenges in conducting prospective pediatric trials.

Main Results:

  • Limited pediatric studies indicate restricted efficacy of amiodarone.
  • Existing research highlights a significant need for further pediatric data.
  • Controlled prospective studies in pediatric resuscitation are ethically challenging.

Conclusions:

  • Healthcare providers must carefully evaluate the available pediatric evidence for amiodarone.
  • The current pediatric data may not support the widespread adoption of amiodarone in treatment regimens.
  • Further investigation is crucial to determine amiodarone's role in pediatric acute resuscitation.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...